ReviewFrontiers in neuroanatomy2015
Oxidative stress and Parkinson's disease.
Review in Frontiers in neuroanatomy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 424 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
424 citing papers in PubMed, 6 syntheses or guidelines pooled it, 863 citations in OpenAlex.
- Association between metabolic syndrome and the risk of Parkinson's disease: a meta-analysis.BMC neurology · 2024Pooled it
- Systematic review and meta-analysis of oxidative stress and antioxidant markers in recurrent aphthous stomatitis.BMC oral health · 2023Pooled it
- Proteins and Transcriptional Dysregulation of the Brain Extracellular Matrix in Parkinson's Disease: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- The association between Parkinson's disease and autoimmune diseases: A systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Association between gout and the development of Parkinson's disease: a systematic review and meta-analysis.BMC neurology · 2022Pooled it
- Dietary Antioxidants and Risk of Parkinson's Disease: A Systematic Review and Dose-Response Meta-analysis of Observational Studies.Advances in nutrition (Bethesda, Md.) · 2022Pooled it
- A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson's disease.BMC neurology · 2024Trial
- The Amino Acid-Neurodegeneration Axis: Excitotoxicity and Oxidative Stress as Context-Dependent Amplifiers of Metabolic Dysfunction.Molecular neurobiology · 2026Review
- Reimagining the contribution of iron in Parkinson's disease.Neurobiology of disease · 2026Review
- Oleuropein Attenuates 6-Hydroxydopamine-Induced Cytotoxicity Through Redox Regulation in Differentiated Dopaminergic Neurons: Potential Involvement of RET-Associated Signalling.International journal of molecular sciences · 2026Article
- Neuroprotective effects of gallic acid in an MPP⁺-induced SH-sy5y cell model of parkinson's disease.Molecular biology reports · 2026Article
- Plant-derived neuroprotective compounds and nanoformulations targeting Parkinson's disease: a semi-systematic review of mechanisms and therapeutic potential.Metabolic brain disease · 2026Review
- Repurposing of doxycycline as a novel therapeutic avenue for management of parkinson's disease.Inflammopharmacology · 2026Review
- Deuterated polyunsaturated fatty acids alleviate in vitro skeletal muscle dysfunction induced by oxidative stress.Free radical biology & medicine · 2026Article
- Serum albumin and uric acid: biomarkers of neurocognitive and physical function in early Parkinson's disease.Experimental brain research · 2026Article
- Peripheral immunochemical considerations in Parkinson disease: sources, targets and crosstalk mechanisms.Journal of translational medicine · 2026Review
- Amelioration of 6-OHDA-Induced Parkinson's Symptoms in Zebrafish Larvae by an Almond Skin Acetonic Extract.International journal of molecular sciences · 2026Article
- Review
- Microbial Metabolism of Levodopa as an Adjunct Therapeutic Target in Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2026Article
- Atherosclerotic-dose TMAO accentuates redox imbalances and motor dysfunctions in a MPTP mouse model of Parkinson's disease.Frontiers in aging neuroscience · 2026Article
364 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson disease (PD) is a chronic, progressive neurological disease that is associated with a loss of dopaminergic neurons in the substantia nigra pars compacta of the brain. The molecular mechanisms underlying the loss of these neurons still remain elusive. Oxidative stress is thought to play an important role in dopaminergic neurotoxicity. Complex I deficiencies of the respiratory chain account for the majority of unfavorable neuronal degeneration in PD. Environmental factors, such as neurotoxins, pesticides, insecticides, dopamine (DA) itself, and genetic mutations in PD-associated proteins contribute to mitochondrial dysfunction which precedes reactive oxygen species formation. In this mini review, we give an update of the classical pathways involving these mechanisms of neurodegeneration, the biochemical and molecular events that mediate or regulate DA neuronal vulnerability, and the role of PD-related gene products in modulating cellular responses to oxidative stress in the course of the neurodegenerative process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.